Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLOVER-1/CLOVER-WaM study of CLR 131 in relapsed or refractory B-cell malignancies
2020-005297-10Phase 2Completed
- Sponsor
- Cellectar Biosciences
- Start
- Jan 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label trial of Iopofosine I-131 in multiple myeloma (MM), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL) and 5 more (2 arms), sponsored by Cellectar Biosciences. Primary endpoint: Clinical benefit rate. Started Jan 2021; status: completed.
02
Drugs
Iopofosine I-131
03
Conditions
multiple myeloma (MM)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Lymphoplasmacytic Lymphoma (LPL)Waldenström macroglobulinemia (WM)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2020-005297-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005297-10.